ASX:CMP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. More Details


Snowflake Analysis

Exceptional growth potential with excellent balance sheet.

Share Price & News

How has Compumedics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CMP has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.4%

CMP

2.9%

AU Medical Equipment

0.5%

AU Market


1 Year Return

-40.0%

CMP

6.7%

AU Medical Equipment

-5.6%

AU Market

Return vs Industry: CMP underperformed the Australian Medical Equipment industry which returned 6.7% over the past year.

Return vs Market: CMP underperformed the Australian Market which returned -5.6% over the past year.


Shareholder returns

CMPIndustryMarket
7 Day3.4%2.9%0.5%
30 Day18.4%11.5%5.0%
90 Day4.7%6.1%2.9%
1 Year-40.0%-40.0%8.0%6.7%-2.3%-5.6%
3 Year25.0%25.0%36.8%30.5%12.4%-1.2%
5 Year32.4%32.4%125.5%109.0%41.5%12.9%

Price Volatility Vs. Market

How volatile is Compumedics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Compumedics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CMP (A$0.45) is trading below our estimate of fair value (A$1.48)

Significantly Below Fair Value: CMP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CMP is unprofitable, so we can't compare its PE Ratio to the AU Medical Equipment industry average.

PE vs Market: CMP is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CMP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CMP is good value based on its PB Ratio (3.7x) compared to the AU Medical Equipment industry average (6.3x).


Next Steps

Future Growth

How is Compumedics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

45.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CMP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: CMP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CMP's is expected to become profitable in the next 3 years.

Revenue vs Market: CMP's revenue (20.5% per year) is forecast to grow faster than the Australian market (4.6% per year).

High Growth Revenue: CMP's revenue (20.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CMP's Return on Equity is forecast to be high in 3 years time (37.1%)


Next Steps

Past Performance

How has Compumedics performed over the past 5 years?

-15.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CMP is currently unprofitable.

Growing Profit Margin: CMP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CMP is unprofitable, and losses have increased over the past 5 years at a rate of 15.7% per year.

Accelerating Growth: Unable to compare CMP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CMP is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (37.2%).


Return on Equity

High ROE: CMP has a negative Return on Equity (-26.79%), as it is currently unprofitable.


Next Steps

Financial Health

How is Compumedics's financial position?


Financial Position Analysis

Short Term Liabilities: CMP's short term assets (A$28.9M) exceed its short term liabilities (A$12.4M).

Long Term Liabilities: CMP's short term assets (A$28.9M) exceed its long term liabilities (A$1.3M).


Debt to Equity History and Analysis

Debt Level: CMP's debt to equity ratio (13.9%) is considered satisfactory.

Reducing Debt: CMP's debt to equity ratio has reduced from 17.5% to 13.9% over the past 5 years.

Debt Coverage: CMP's debt is well covered by operating cash flow (177.1%).

Interest Coverage: Insufficient data to determine if CMP's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Compumedics's current dividend yield, its reliability and sustainability?

2.13%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CMP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CMP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CMP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CMP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CMP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average board tenure


CEO

David Burton (61 yo)

no data

Tenure

AU$249,967

Compensation

Dr. David Burton, Ph.D. founded Compumedics Ltd. in 1987 and serves as its Executive Chairman and Chief Executive Officer. Dr. Burton serves as Executive Chairman and Chief Executive Officer of Compumedics ...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD177.13K) is below average for companies of similar size in the Australian market ($USD277.02K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
David Burton
Founderno dataAU$249.97k1.15%
A$ 919.3k
David Lawson
CFO, Company Secretary & Executive Director7yrsAU$281.18k1.96%
A$ 1.6m
Ian Colrain
Member of Medical Advisory Board3.83yrsno datano data
Patrice Bourgin
Member of Medical Advisory Board3.83yrsno datano data
John Ebersole
Member of Medical Advisory Board3.83yrsno datano data
Tucson Dunn
Independent Non-Executive Director2.42yrsno datano data

3.8yrs

Average Tenure

Experienced Board: CMP's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Compumedics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Compumedics Limited
  • Ticker: CMP
  • Exchange: ASX
  • Founded: 1987
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$79.723m
  • Shares outstanding: 177.16m
  • Website: https://www.compumedics.com.au

Location

  • Compumedics Limited
  • 30-40 Flockhart Street
  • Abbotsford
  • Victoria
  • 3067
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CMPASX (Australian Securities Exchange)YesOrdinary SharesAUAUDDec 2000
CMPCHIA (Chi-X Australia)YesOrdinary SharesAUAUDDec 2000

Biography

Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics produ ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 10:42
End of Day Share Price2020/10/20 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.